IGX Archives - Page 3 of 8

Developments

IntelGenx receives new U.S. patent on VersaFilm technology

IntelGenx Corp. (TSX:IGX; OTCQB:IGXT) received U.S. Patent No. 11,471,406 from the United States Patent and Trademark Office, with claims for modulating drug absorption in oral film dosage form designed for sublingual...

October 20, 2022

Developments

IntelGenx submits response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx (TSX:IGX; OTCQB:IGXT) responded to the complete response letter (CRL) for its 505(b)(2) NDA for RIZAPORT VersaFilm received from the FDA in March 2020. “We have been encouraged by our interactions with...

October 18, 2022

Developments

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

IntelGenx (TSX:IGX; OTCQB:IGXT) updated its collaboration with strategic partner, atai Life Sciences (NASDAQ:ATAI), which has begun a first-in-human Phase 1 study for the development of novel formulations of...

October 13, 2022

Developments

Enrollment reaches halfway in IntelGenx Phase 2a Montelukast VersaFilm AD trial

Patient enrollment in the IntelGenx (TSX:IGX; OTCQB:IGXT) ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) has reached the halfway mark. This...

September 8, 2022

Developments

IntelGenx oral film for ED featured in WebMD

The current issue of WebMD features up-and-coming buccal film and buccal patch technologies to deliver drug via the inside lining of the cheek and highlights the sublingual delivery for erectile dysfunction from...

April 21, 2022

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Developments

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) intends to resume patient screening in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) following Health Canada’s...

October 12, 2021

Developments

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) received final approval to graduate to the Toronto Stock Exchange from the TSX Venture Exchange. The company’s common stock; 8% convertible debentures, with a maturity date...

October 5, 2021

Developments

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

IntelGenx (TSXV:IGX; OTCQB:IGXT) and Aquestive Therapeutics (NASDAQ:AQST), its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic...

September 30, 2021

Developments

Heritage Cannabis launches first Opticann CB4 medical products in Canada

Heritage Cannabis (CSE:CANN; OTCQX:HERTF) announced that Opticann, the medical brand and subsidiary of Heritage, is launching its first suite of CB4 branded products and has launched Opticann.ca in Canada...

September 20, 2021

Tag - IGX

IntelGenx receives new U.S. patent on VersaFilm technology

IntelGenx submits response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

Enrollment reaches halfway in IntelGenx Phase 2a Montelukast VersaFilm AD trial

IntelGenx oral film for ED featured in WebMD

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx to resume Phase 2a patient screening with Montelukast VersaFilm in AD

IntelGenx cleared to graduate to Toronto Stock Exchange

IntelGenx, Aquestive in pact with men’s health company for Tadalafil oral films in U.S.

Heritage Cannabis launches first Opticann CB4 medical products in Canada

General

More